GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
1.680
-0.069 (-3.97%)
At close: Aug 13, 2025, 4:00 PM
1.680
0.00 (0.00%)
After-hours: Aug 13, 2025, 4:00 PM EDT
GT Biopharma Employees
GT Biopharma had 1 employees as of December 31, 2024. The number of employees decreased by 1 or -50.00% compared to the previous year.
Employees
1
Change (1Y)
-1
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$11,672,000
Market Cap
5.29M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GTBP News
- 2 days ago - GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 - GlobeNewsWire
- 2 months ago - GT Biopharma Appoints New Member to its Board of Directors - GlobeNewsWire
- 3 months ago - GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals - GlobeNewsWire
- 6 months ago - GT Biopharma Announces Exercise of Warrants - GlobeNewsWire
- 9 months ago - GT Biopharma Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 11 months ago - GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 11 months ago - GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 - GlobeNewsWire
- 1 year ago - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia - GlobeNewsWire